Molluscum Contagiosum Clinical Trial
Official title:
A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in approximately 340 subjects with MC. After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 2:1 (active:vehicle). Subjects receiving current treatment for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior to randomization. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study. Subjects or their caregivers will continue to treat the area until the next scheduled visit even if the lesion(s) clear. If the investigator determines all lesions are cleared at a clinic visit, the treatment may stop. Subjects will visit the clinic at Screening/Baseline, Week 2, Week 4, Week 8, Week 12. In addition, subjects will be seen in the clinic for a safety follow-up at Week 24. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03017846 -
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
|
Phase 2 | |
Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
Completed |
NCT04535531 -
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
|
Phase 3 | |
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT05897112 -
Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum
|
Phase 1 | |
Withdrawn |
NCT05536882 -
MC RCT - BPO vs Adapalene
|
Phase 3 | |
Completed |
NCT03377790 -
Cantharidin Application in Molluscum Patients-1
|
Phase 3 | |
Completed |
NCT01348386 -
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
|
Phase 2/Phase 3 | |
Completed |
NCT05634460 -
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum
|
Phase 1 | |
Completed |
NCT03186378 -
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
|
Phase 2 | |
Completed |
NCT03927716 -
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
|
Phase 3 | |
Recruiting |
NCT04476186 -
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
|
N/A | |
Completed |
NCT02665260 -
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
Completed |
NCT03436615 -
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
|
Phase 2 | |
Recruiting |
NCT02759900 -
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
|
N/A | |
Completed |
NCT05680181 -
Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
|
||
Completed |
NCT03077750 -
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
|
Phase 2 | |
Terminated |
NCT02024581 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
Completed |
NCT03377803 -
Cantharidin Application in Molluscum Patients
|
Phase 3 | |
Withdrawn |
NCT03336372 -
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
|
Early Phase 1 |